Nordion to Host European-Based Educational and Scientific Meetings for Liver Cancer Specialists
Meetings designed to support TheraSphere® treatment growth and expansion in Europe
OTTAWA, Ontario--(BUSINESS WIRE)-- Nordion Inc. (NDZ) (TSX: NDN) (NYSE: NDZ), a leading provider of products and services for the prevention, diagnosis and treatment of disease, will host two upcoming educational and scientific meetings to support the growth and expansion of TheraSphere® treatment in Europe. On April 11 12, Nordion will host its 3rdEuropean TheraSphere User Group Meeting in Vienna, Austria and on April 18, Nordion will offer a Satellite Symposium at the 3rd Interdisciplinary Treatment of Liver Tumors (ITLT) Meeting in Essen, Germany.
These meetings provide physicians with an opportunity for interactive, real-time discussions on industry best practices and trends in radioembolization and liver cancer therapy, said Steve West, Nordion CEO and Chief Operating Officer, Targeted Therapies. With the objective of expanding the adoption of TheraSphere in Europe and further developing our clinical program, these events help us share the latest developments in radioembolization to a broad physician base from various liver cancer disciplines.
The 3rd European TheraSphere User Group Meeting will cover a variety of topics over two days with a focus on current and future trends in radioembolization presented by speakers from Italy, Germany, France and the United States.
The ITLT Satellite Symposium titled Clearly Targeted! Looking Beyond Systemic Therapies for the Treatment of Liver Cancer is intended to provide attendees with the latest data on radioembolization from Nordions three European TheraSphere Centres of Excellence. The symposiums Chairman, Professor Stefan Pluntke, a medical oncologist from Essen Mitte hospital, will moderate the following three sessions from key presenters:
- Targeted Liver Cancer Therapy in the Windy City. The Chicago Experience with TheraSphere®, Dr. Riad Salem, Interventional Oncologist, Northwestern University, Chicago, Illinois
- The Future is Clear. The Milan Experience with TheraSphere®, Professor Vincenzo Mazzaferro, Liver Transplant Surgeon, Istituto Tumori, Milan, Italy
- The Lesson from Essen. Latest Insights on the Use of TheraSphere®, Professor Jörg Schlaak, Gastroenterologist and Hepatologist, Essen University Hospital, Essen, Germany
For more information on these events or to register please visit www.therasphere.com.
TheraSphere is a liver cancer therapy that consists of millions of small glass beads (20 to 30 micrometers in diameter) containing radioactive yttrium-90 (Y-90). The product is injected by physicians into the artery of the patients liver through a catheter, which allows the treatment to be delivered directly to the tumour via blood flow.
In the US, TheraSphere is used for radiation treatment of patients with unresectable hepatocellular carcinoma (HCC), the most common form of primary liver cancer, and can be used as a bridge to surgery or transplantation in these patients. It is also indicated for the treatment of HCC patients with partial or branch portal vein thrombosis (PVT). TheraSphere is approved by the U.S. Food and Drug Administration (FDA) under a Humanitarian Device Exemption (HDE). HDE approvals are based on demonstrated safety and probable clinical benefit. However, effectiveness of the indication for use has not been established.
TheraSphere is used in the European Union and in Canada for the treatment of hepatic neoplasia in patients who have appropriately positioned arterial catheters.
Common side effects include mild to moderate fatigue, pain and nausea for about a week. Physicians describe these symptoms as similar to those of the flu. Some patients experience some loss of appetite and temporary changes in several blood tests. For details on rare or more severe side effects, please refer to the TheraSphere package insert/instructions for use at www.nordion.com/therasphere.
About Nordion Inc.
Nordion Inc. (TSX: NDN) (NYSE: NDZ) is a global health science company that provides market-leading products used for the prevention, diagnosis and treatment of disease. We are a leading provider of targeted therapies, sterilization technologies, and medical isotopes that benefit the lives of millions of people in more than 60 countries around the world. Our products are used daily by pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics and research laboratories. Nordion has approximately 500 highly skilled employees worldwide. Find out more at www.nordion.com and follow us at http://twitter.com/NordionInc.
Shelley Maclean, (613) 592-3400 x. 2414
Cell: (613) 291-3689
Ana Raman, (613) 595-4580
Source: Nordion Inc.Copyright Business Wire 2013